Email
Mot de passe
Pour plus de facilité, laissez cette case cochée. Sur les appareils partagés, nous vous conseillons de vous déconnecter d'Euroquity à la fin de votre utilisation
Email

Vous allez recevoir un email pour créer un nouveau mot de passe

Localisation

Choisissez votre pays

et votre langue

Bonjour ,

Bienvenue sur votre profil personnel. Votre carte de visite professionnelle présente votre activité principale. Elle sera visible sur EuroQuity.

% complété

%

medal 1
Ce profil est validé par 1 label.

Company

EpiDisease SL

EpiDisease SL_logo
8
EQ SCORE

L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.

EpiDisease is an epigenetics technology-based company that develops and commercialises a pipeline of epigenetic proprietary products for earlier and accurate diagnostic and prognostic of human diseases and epigenetic specialised services.

Valencia, Valencia, Spain

Send a message

Anglais

EpiDisease SL

Anglais

EpiDisease S.L. is a spin-off founded in 2014 by researchers from the Centre for Biomedical Network Research (CIBER-ISCIII) and the University of Valencia from Spain to offer society new applications and services based on the use of epigenetics.

We develops and commercialises a pipeline of epigenetic proprietary products for earlier and accurate diagnostic and prognostic of human diseases and epigenetic specialised services.

Our first...

See more

EpiDisease S.L. is a spin-off founded in 2014 by researchers from the Centre for Biomedical Network Research (CIBER-ISCIII) and the University of Valencia from Spain to offer society new applications and services based on the use of epigenetics.

We develops and commercialises a pipeline of epigenetic proprietary products for earlier and accurate diagnostic and prognostic of human diseases and epigenetic specialised services.

Our first product is intended for Adolescent Idiopathic Scoliosis (AIS), a three-dimensional spinal deformity that affects 1.3M adolescents in Europe, characterised by pain, aesthetic deformity, immense psychological stress and alterations in pulmonary function and is, therefore, an increasing concern for both patients and their relatives. About 10% of AIS can progress towards severe outcome, which requires costly and risky surgery. To date, it is not possible to predict either spine deformity progression or efficacy of braces, so patients are followed up by multiple X-ray radiographs, an approach that increases the risk of cancer in adulthood. Moreover, despite X-rays having no prognostic capability, a fact that clearly evidences the need for developing new methods to improve AIS management.​

EpiDisease has developed ScoliPro®a panel of microRNAs detected in blood to provide a risk factor which correlates with the severity and risk of disease progression, offering a reliable solution to predict spine deformity progression.

Certifications

Seal of Excellence
The Seal of Excellence is a quality label awarded to project proposals submitted to Horizon 2020 which succeeded a highly competitive evaluation process by independent experts, but did not received funding due to budget limits. This quality label is a guarantee for investors to find high standard project proposals from European SMEs with growth potential.
1113 Entities

Communities